Field Trip is a mental wellness company that focuses on psychedelics and psychedelic-enhanced psychotherapy. In February 2020 they closed their Series A funding round, having raised $8.5m USD. The Company listed on the CSE on 6th Oct, 2020.
According to their website: “Field Trip is leading the medical and scientific re-emergence of psychedelics and psychedelic-enhanced therapies. Through Field Trip Health’s intentionally-designed, technology-empowered clinics providing psychedelic therapies, Field Trip Digital’s apps and resources scaling our protocols globally, and Field Trip Discovery, our drug development division developing the next generation of psychedelic molecules, we help people through an integrated, evidence-based approach to healing and thriving.”
We pitched Ronan Levy – Founder & Executive Chairman of Field Trip Health – a variety of questions about Field Trip, as well as some broader questions about investing in the space.